Chinese authorities approve seasoned Novo Nordisk combination treatment
A 2022 New Year's resolution for Novo Nordisk will be to launch the combination treatment type 2 diabetes, Xultophy, in China, a goal made possible by the national authority's approval of the seven-year-old drug.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN
The treatment Xultophy, which combines Novo Nordisk's long-acting insulin Tresiba with the GLP-1 analog Victoza, is now headed to the Chinese market.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
WHO adds Novo Nordisk insulin to essential medicine lists
For subscribers
.jpg&w=384&q=75)
